Alzheimer\u2019s disease<\/a>, Parkinson\u2019s disease, Huntingon\u2019s disease, and\u00a0familial amyloidotic polyneuropathy and cardiomyopathy. Although the exact\u00a0mechanism of toxicity and the identity of the toxic species remain unknown, there is\u00a0strong genetic and pathologic evidence that the process of amyloidogenesis is closely\u00a0linked to these maladies. The mechanisms by which proteins assemble into amyloid\u00a0vary, as do the reasons why some people are more likely to develop amyloid diseases\u00a0than others. Some of the proteins that form amyloid and putatively cause amyloid disease, such as A\u03b2, huntingtin, and \u03b1-synuclein, are thought to be intrinsically<\/p>\ndisordered. These assemble into amyloid in a highly concentration dependent process to\u00a0form a cross \u03b2-sheet amyloid aggregate. Other amyloidogenic proteins, such as\u00a0transthyretin, \u03b2<sub>2<\/sub>-microglobulin, and the prion protein, exhibit well-defined native 3-dimensional structures and only form aggregates after partial unfolding or\u00a0misfolding. Many amyloid diseases are familial, i.e. they are caused by mutations in\u00a0genes encoding the protein that forms amyloid or a protein that is involved in the\u00a0proteolytic processing of an amyloid precursor protein. For example, there are over one\u00a0hundred point mutations in transthyretin that destabilize its native tetrameric fold,\u00a0increasing the partially-folded monomer population and thus enhancing its\u00a0amyloidogenicity, leading to familial amyloid polyneuropathy or cardiomyopathy. A\u00a0point mutation at position 187 from an Asp to an Asn or Tyr in the protein gelsolin\u00a0eliminates a Ca<sup>2+<\/sup>\u00a0binding site, destabilizing that protein domain and making it susceptible\u00a0to aberrant cleavage first by furin in the Golgi compartment and then by a membraneassociated type I matrix metalloprotease outside the cell, yielding 8 and 5 kDa\u00a0fragments. These peptide fragments then aggregate into amyloid, enabled by\u00a0glycosaminoglycans, resulting in familial amyloidosis of the Finnish type or\u00a0gelsolin amyloid disease. Although specific mutations in some proteins can lead to earlyonset amyloidoses, e.g. the L55P mutation in transthyretin leads to familial amyloid\u00a0polyneuropathy in the second decade, much more frequently wild-type proteins will\u00a0aggregate and cause sporadic disease in the aged. It remains unclear why amyloid\u00a0diseases tend to affect the elderly, although it is becoming more clear that signaling\u00a0pathways that maintain the proteome and strongly influence aging either share common\u00a0components or in some cases are one in the same. For example, the proteostasis network capacity, which is strongly influenced by the unfolded protein response and the heat shock response, strongly influences the etiology of these diseases. Additionally, how the formation of amyloid leads to the apparently unique phenotype of each disease is still not well understood; whether deposited amyloid fibrils or intermediates leading to that deposition cause disease and how those species exhibit toxicity to cells are current topics of investigation. Understanding what triggers the onset of sporadic amyloid diseases not associated with any known mutation and the factors that hasten disease progression is of great interest. Learning more about these factors should lead to knew treatment strategies for these diseases.<\/p>\n
Reference:<\/p>\n
Siegel, S. J. (2008). Structure and energetics of amyloid. The Scripps Research Institute.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
The term \u2018amyloid\u2019\u00a0was first used in 1854 by Rudolph Virchow to describe\u00a0abnormal brain tissue that was stained by iodine, suggesting that it was starch-like. It\u00a0was later discovered that the amyloid …<\/p>\n","protected":false},"author":1,"featured_media":487,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[75],"tags":[114,80],"_links":{"self":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/485"}],"collection":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/comments?post=485"}],"version-history":[{"count":1,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/485\/revisions"}],"predecessor-version":[{"id":486,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/posts\/485\/revisions\/486"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/media\/487"}],"wp:attachment":[{"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/media?parent=485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/categories?post=485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.creative-peptides.com\/blog\/wp-json\/wp\/v2\/tags?post=485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}